$2.26
▲ +$0.06
(+2.73%)
Vol 206K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$143.1M
ROE
-53.6%
Margin
-400.1%
D/E
0.00
Beta
2.84
52W
$1–$3
Wall Street Consensus
11 analysts · Apr 20265
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.05 | $0.60 | +$0.55 |
| Sep 2025 | $-0.09 | $-0.07 | +$0.02 |
| Jun 2025 | $-0.07 | $-0.08 | $-0.01 |
| Mar 2025 | $-0.06 | $-0.08 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $2.3M | $1.3M | $1.9M | $67.3M |
| Net Income | — | -$6.1M | -$7.2M | -$7.3M | -$7.0M | $56.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.8% | -34.8% | -34.8% | -34.8% | -34.8% | -53.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -584.1% | -87.5% | -87.5% | -87.5% | -87.4% | -400.1% |
| Gross Margin | -32.5% | 62.3% | 62.3% | 62.3% | 62.3% | 7.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.74 | 4.74 | 4.74 | 4.74 | 4.74 | 4.38 |
Key Ratios
ROA (TTM)
-25.4%
P/S (TTM)
20.73
P/B
2.5
EPS (TTM)
$-0.30
Rev Growth 3Y
+66.8%
52W High
$2.66
52W Low
$1.13
$1.13
52-Week Range
$2.66
Financial Health
Net Debt
-$87.6M
Cash
$90.6M
Total Debt
$3.0M
As of Dec 31, 2025
How does CGEN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CGEN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
20.7
▲
61%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.5
▲
1%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CGEN profitability vs Biotechnology peers
ROE
-53.6%
▲
20%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-400.1%
▼
40%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
7.4%
▼
91%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-25.4%
▲
46%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CGEN financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.4
▼
1%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
2.8
▲
193%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CGEN fundamentals radar
CGEN
Peer median
Industry
CGEN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CGEN vs peers: key metrics
Top Holders
Top 5: 8.38%SilverArc Capital Managemen…
3.72%
$7.1M
Renaissance Technologies, L…
1.56%
$3.0M
Nomura Asset Management Int…
1.09%
$2.1M
Morgan Stanley
1.08%
$2.1M
Taylor Frigon Capital Manag…
0.93%
$1.8M
As of Dec 31, 2025